surmount-1 tirzepatide non-diabetic obesity weight loss FDA Grants a New Indication for Management Tirzepatide for the Maintenance of

Patients seeking GLP-1-based therapy have several evidence-based options available through prescription from licensed healthcare providers

To address this need, we conducted a systematic review and meta-analysis to evaluate and compare the efficacy of GLP-1 RAs in promoting weight loss and modulating body composition in individuals with overweight or obesity with or without T2DM

The market's value has tripled in 18 months, with Mounjaro's share more than doubling to 52% at the end of January from 21% in the quarter ended April 2025, helped largely by regulatory approval for chronic weight management, Saad added

Elahi D

This is one reason why comprehensive medical weight-loss programs continue to produce stronger long-term outcomes than medication-only approaches

Jiang et al